231 related articles for article (PubMed ID: 27725533)
1. Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.
Masuda T; Murakami T; Igarashi Y; Okabe K; Kobayashi T; Takeda SI; Saito T; Sekiguchi C; Miyazawa Y; Akimoto T; Saito O; Muto S; Nagata D
Intern Med; 2016; 55(19):2759-2764. PubMed ID: 27725533
[TBL] [Abstract][Full Text] [Related]
2. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
[TBL] [Abstract][Full Text] [Related]
3. Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics.
Iwatani H; Yamato M; Bessho S; Mori Y; Notsu S; Asahina Y; Koizumi S; Kimura Y; Shimomura A
Intern Med; 2022 Sep; 61(17):2561-2565. PubMed ID: 35110480
[TBL] [Abstract][Full Text] [Related]
4. Role of Chronic Use of Tolvaptan in Patients with Heart Failure Undergoing Peritoneal Dialysis.
Mori T; Kurasawa N; Ohsaki Y; Koizumi K; Sato S; Oba-Yabana I; Shimada S; Sato E; Naganuma E; Tsuchikawa M; Ito S
Adv Perit Dial; 2016; 32():39-45. PubMed ID: 28988588
[TBL] [Abstract][Full Text] [Related]
5. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.
Masuda T; Ohara K; Nagayama I; Matsuoka R; Murakami T; Nakagawa S; Oka K; Asakura M; Igarashi Y; Fukaya Y; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Nagata D
Int Urol Nephrol; 2019 Sep; 51(9):1623-1629. PubMed ID: 31161520
[TBL] [Abstract][Full Text] [Related]
6. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
Nagayama I; Masuda T; Nakagawa S; Murakami T; Ohara K; Matsuoka R; Kobayashi T; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
Intern Med; 2019 Jun; 58(11):1587-1591. PubMed ID: 30713322
[TBL] [Abstract][Full Text] [Related]
7. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
Iwatani H; Kawabata H; Sakaguchi Y; Yamamoto R; Hamano T; Rakugi H; Isaka Y
Nephron; 2015; 130(1):8-12. PubMed ID: 25926290
[TBL] [Abstract][Full Text] [Related]
8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
9. Tolvaptan Efficiently Reduces Intracellular Fluid: Working Toward a Potential Treatment Option for Cellular Edema.
Kawabata H; Iwatani H; Yamamichi Y; Shirahase K; Nagai N; Isaka Y
Intern Med; 2019 Mar; 58(5):639-642. PubMed ID: 30449775
[TBL] [Abstract][Full Text] [Related]
10. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
[TBL] [Abstract][Full Text] [Related]
11. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
[TBL] [Abstract][Full Text] [Related]
12. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB
BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients.
Tanaka A; Katsuno T; Ozaki T; Sakata F; Kato N; Suzuki Y; Kosugi T; Kato S; Tsuboi N; Sato W; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
Acta Cardiol; 2015 Apr; 70(2):217-23. PubMed ID: 26148383
[TBL] [Abstract][Full Text] [Related]
14. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
16. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
Ohara K; Masuda T; Morinari M; Okada M; Miki A; Nakagawa S; Murakami T; Oka K; Asakura M; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Nagata D
Diabetol Metab Syndr; 2020; 12():37. PubMed ID: 32377235
[TBL] [Abstract][Full Text] [Related]
17. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
[TBL] [Abstract][Full Text] [Related]
18. Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
Takagi K; Sato N; Ishihara S; Iha H; Kobayashi N; Ito Y; Nohara T; Ohkuma S; Mitsuishi T; Ishizuka A; Shigihara S; Sone M; Nakama K; Tokuyama H; Omote T; Kikuchi A; Nakamura S; Yamamoto E; Ishikawa M; Amitani K; Takahashi N; Maruyama Y; Imura H; Shimizu W
J Cardiol; 2020 Nov; 76(5):499-505. PubMed ID: 32665162
[TBL] [Abstract][Full Text] [Related]
19. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
[TBL] [Abstract][Full Text] [Related]
20. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Takada T; Masaki T; Hoshiyama A; Toki T; Kamata Y; Shichiri M
Nephrology (Carlton); 2018 Sep; 23(9):883-886. PubMed ID: 29665203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
